Você procurou por: verificeringsrækkefølge med buffer (Dinamarquês - Inglês)

formulering med buffer
formulation with buffer

didanosintabletterne med buffer.
didanosine buffered tablets.

didanosin formulering med buffer
didanosine formulation with buffer

didanosin (tabletter med buffer)
didanosine (buffered tablets)

reyataz med ritonavir bør gives 2 timer før eller 1 time efter lægemidler med buffer.
reyataz with ritonavir should be administered 2 hours before or 1 hour after buffered medicinal products.

didanosin (tabletter med buffer) 200 mg/ stavudin 40 mg, begge som enkeltdoser
didanosine (buffered tablets) 200 mg/ stavudine 40 mg, both single dose (atazanavir 400 mg

interaktionsmekanismen er nedsat opløselighed af atazanavir på grund af en stigning i ph, der skyldes det syrehæmmende middel i didanosintabletterne med buffer.
the mechanism of interaction is a reduced solubility of atazanavir with increasing ph related to the presence of anti-acid agent in didanosine buffered tablets.

plasmakoncentrationen af atazanavir kan falde, hvis gastrisk ph øges ved samtidig administration af antacida, inklusive lægemidler med buffer, og reataz.
reduced plasma concentrations of atazanavir may be the consequence of increased gastric ph if antacids, including buffered medicinal products, are administered with reyataz.

plasmakoncentrationen af atazanavir kan falde pga. gastrisk ph-stigning, hvis antacida, inklusive lægemidler med buffer, administreres samtidigt med evotaz.
reduced plasma concentrations of atazanavir may be the consequence of increased gastric ph if antacids, including buffered medicinal products, are administered with evotaz.

didanosin (tabletter med buffer) 200 mg/ stavudin 40 mg, begge som enkeltdoser (atazanavir 400 mg som enkeltdosis)
products (dose in mg)

antacida og lægemidler indeholdende buffere:nedsatte plasmakoncentrationer af atazanavir kan blive konsekvensen af øget gastrisk ph, hvis antacida, inklusive lægemidler med buffer, administreres samtidig med reyataz med ritonavir.
70 antacids and medicinal products containing buffers: reduced plasma concentrations of atazanavir may be the consequence of increased gastric ph if antacids, including buffered medicinal products, are administered with reyataz with ritonavir.

reyataz / ritonavir bør administreres 2 timer inden eller 1 time efter antacida eller lægemidler med buffere.
reyataz/ ritonavir should be administered 2 hours before or 1 hour after antacids or buffered medicinal products.

det andet indholdsstof er steril dulbecco’s modified eagles medium (dmem) behandlet med buffer, en væske indeholdende aminosyrer, vitaminer, salte og kulhydrater til opbevaring af cellerne i hætteglasset.
the other ingredient is sterile, buffered dulbecco’s modified eagles medium (dmem), a liquid containing amino acids, vitamins, salts and carbohydrates to store the cells in the vial.

atazanavir, doseret 1 time efter ↔1, 03 ↑1, 12 ↔1, 03 ddi+d4t (0, 64; 1, 67) (0, 67; 1, 18) (0, 61; 1, 73) (fastende) atazanavir- koncentrationen faldt meget ved samtidig administration med didanosin (tabletter med buffer) og stavudin.
atazanavir, dosed ↔ 1.03 ↑ 1.12 ↔ 1.03 1 hr after ddi+d4t (0.64, 1.67) (0.67, 1.18) (0.61, 1.73) (fasted) atazanavir concentrations were greatly decreased when co-administered with didanosine (buffered tablets) and stavudine.